Geron Corp. (GERN)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Company performance

Current Price

as of Dec 27, 2024

$3.35

P/E Ratio

N/A

Market Cap

$2.03B

Description

Geron Corp. operates as a biotechnology company. It develops a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies. The firm develops therapeutic products for oncology. The company was founded by Michael D. West on November 28, 1990 and is headquartered in Foster City, CA.

Metrics

Overview

  • HQFoster City, CA
  • SectorHealth Technology
  • IndustryBiotechnology
  • TickerGERN
  • Price$3.35+1.52%

Trading Information

  • Market cap$2.03B
  • Float93.41%
  • Average Daily Volume (1m)10,635,882
  • Average Daily Volume (3m)9,084,135
  • EPS-$0.32

Company

  • Revenue$29.48M
  • Rev growth (1yr)17,138.41%
  • Net income-$26.45M
  • Gross margin97.68%
  • EBITDA margin-99.09%
  • EBITDA-$28.01M
  • EV$2.75B
  • EV/Revenue93.35
  • P/EN/A
  • P/S75.25
  • P/B6.91
Documents